Cancer Medicine · 2016 · 100 citations · 14 references
MedicinePharmacokineticsPharmacologyCancer PharmacologyClinical PharmacologyPharmacodynamicsOncology PharmacologyOral Anticancer AgentsPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsPharmacokinetics Of Anticancer DrugsCompetitive Binding StudiesMap KinasesMetabolite PharmacokineticsMetabolite-parent Drug RelationshipsMetastatic Gastrointestinal Stromal TumorsTotal Drug ConcentrationsTumor Angiogenesis Signaling
Abstract Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory metastatic colorectal cancer. In clinical studies, steady‐state exposure to the M‐2 and M‐5 metabolites of regorafenib was similar to that of the parent drug; however, the contribution of these metabolites to the overall observed clinical activity of regorafenib cannot be investigated in clinical trials. Therefore, we assessed the pharmacokinetics and pharmacodynamics of regorafenib, M‐2, and M‐5 in vitro and in murine xenograft models. M‐2 and M‐5 showed similar kinase inhibition profiles and comparable potency to regorafenib in a competitive binding assay. Inhibition of key target kinases by all three compounds was confirmed in cell‐based assays. In murine xenograft models, oral regorafenib, M‐2, and M‐5 significantly inhibited tumor growth versus controls. Total peak plasma drug concentrations and exposure to M‐2 and M‐5 in mice after repeated oral dosing with regorafenib 10 mg/kg/day were comparable to those in humans. In vitro studies showed high binding of regorafenib, M‐2, and M‐5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma. Estimated free plasma concentrations of regorafenib and M‐2, but not M‐5, exceeded the IC 50 at human and murine VEGFR2, suggesting that regorafenib and M‐2 are the primary contributors to the pharmacologic activity of regorafenib in vivo.
14
A small molecule–kinase interaction map for clinical kinase inhibitors
Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text
George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +8
Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17
Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 816 citations
Medicine, Oncology, Pharmacotherapy +10